Responding patients showed long-term T-cell activation after the first infusion of CD20-TCB at doses from 0.6mg and above. T-cell activation was demonstrated by 2-4-fold elevation of T-cell activation markers such as Ki67, HLA-DR, PD-1, ICOS, OX40, and 4-1BB, which was sustained ...
在2020年EHA会议上,Michael J. Dickinson 就CD20-TCB在复发或难治性(R / R)非霍奇金淋巴瘤(NHL)中I期临床试验中的疗效和安全性做了口头报告(Abstract: S241 )。CD20-TCB(RG6026)是一种新型的T细胞接合双特异性抗体,包含两个CD20片段抗原...
Conclusions: CD20‐TCB is a novel 2:1 format T‐cell‐engaging bispecific antibody which displays highly promising clinical activity in heavily‐pretreated NHL. Keywords: B‐cell lymphoma; CD20; immune system. Disclosures: Dickinson, M: Consultant Advisory Role: Roche; Honoraria: Roche. Morsch...
描述: 格菲妥单抗。关键字: RO7082859 |RG 6026 |CD20-TCB;RO7082859 |RG 6026 |CD20-TCB | 原创作者:上海陶术生物科技有限公司 标签:格菲妥单抗 Glofitamab;格菲妥单抗RO7082859|||RG 6026|||CD20-TCB;RO7082859|||RG 6026|||CD20-TCB产品询价/message 留言框 感兴趣的产品: * 您的单位: * 您的...
资讯 会议 课程 空中讲坛关于我们 | 产品大全 | 营销服务 | 联系我们 | 加入我们 | 友情链接 | 用户服务协议 | 隐私保护 | 免责条款 | 沪ICP备14018915号-1 | 增值电信业务经营许可证 Copyright©2001-2020 bioon.com 版权所有 不得转载. 著作权声明 | 法律声明 | 互联网药品信息服务资格证书((沪)-...
CD20-TCB (RG6026) is a novel T-cell-engaging bispecific (TCB) antibody with a '2:1' molecular format comprising two fragment antigen binding regions that bind CD20 (on the surface of B cells) and one that binds CD3 (on the surface of T cells). CD20-TCB offers the potential for ...
CD20-TCBBispecific T-cell recruiting antibodies are emerging as a potent immunotherapeutic class in the treatment of B-cell malignancies and act by simultaneously targeting antigens on T-cells and malignant cells to effect tumor cell death. Glofitamab is a novel full-length IgG-like CD20-CD3 ...
CD20 TCB is a new bispecific antibody with IgG-like pharmacokinetic properties whose unique "2:1" structure leads to increased tumor antigen avidity, T cell activation, and tumor cell killing, as compared to other T cell engaging bispecific antibody molecular formats. The molecule comprises two ...
Introduction: CD20-TCB (RG6026) is a novel T-cell-engaging bispecific (TCB) antibody with a '2:1' molecular format that comprises two fragment antigen binding regions that bind CD20 (on the surface of B cells) and one that binds CD3 (on the surface of T cells). CD20-TCB offers the ...